# US 2022/0031870 A1 · Metal complexes and fluorination thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031870 A1
- Document ID: US20220031870A1
- Status: Published application
- Kind: A1
- Application number: 17/395,319
- Filed: 2021-08-05
- Published: 2022-02-03
- Earliest claimed: 2013-05-03
- Assignees: Ge Healthcare Limited; University of Southampton
- Applicants: GE Healthcare Limited; University of Southampton
- Inventors: Rajiv BHALLA; Gill REID; William LEVASON
- Web page: https://patentgrep.com/patent/US20220031870A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- C07D 255/02: not condensed with other rings
- C07F 5/003: {without C-Metal linkages}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilized to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of preparation of an imaging agent which comprises an 18F-labelled compound of Formula I:
where:
X1, X2 and X3 are independently Br, Cl, 19F or 18F, with the proviso that at least one of X1, X2 and X3 is 18F;
M is Al3+, Ga3+, In3+, Sc3+, Y3+, Ho3+, Er3+, Tm3+, Yb3+ or Lu3+;
Z1 is of Formula Za
where each R3 is independently H, C1-4 alkyl, C2-4 alkoxyalkyl, C1-4 hydroxyalkyl, a Y group or a Q group;
each f is independently 1;
p is 1, 2 or 3;
y is 0 or 1;
Y is independently -(A′)x-Y1 or -(A′)x-Y1-Q where each A1 is independently —CH2— or —O—, provided that Y does not comprise any —O—O— bonds;
wherein x is an integer of value 1 to 6; and
Y1 is —NHRa, —NH(CH2)2NHRa, —NH(CH2)3NHRa, —(C═O)NHRa, —NH(C═O)Ra, —NH(C═NH)NHRa, —ORa or a Y3 group;
Y3 is Arg, Lys, Asn, Gln, Ser, Thr or Tyr;
wherein Ra is independently H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkoxyalkyl or C1-4 hydroxyalkyl;
Q is -L-[BTM];
L is a synthetic linker group of formula -(A)m- wherein each A is independently —CR2—, —CR═CR—, —C≡C—, —CR2CO2—, —CO2CR2—, —NRCO—, —CONR—, —CR═N—O—, —NR(C═O)NR—, —NR(C═S)NR—, —SO2NR—, —NRSO2—, —CR2OCR2—, —CR2SCR2—, —CR2NRCR2—, a C4-8 cycloheteroalkylene group, a C4-8 cycloalkylene group, —Ar—, —NR—Ar—, —O—Ar—, —Ar—(CO)—, an amino acid, a sugar or a monodisperse polyethyleneglycol (PEG) building block,
wherein each R is independently chosen from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkoxyalkyl or C1-4 hydroxyalkyl;
m is an integer of value 1 to 20;
each Ar is independently a C5-12 arylene group, or a C3-12 heteroarylene group;
BTM is a biological targeting moiety chosen from: a 3-100 mer peptide, an enzyme substrate, an enzyme antagonist, an enzyme agonist, an enzyme inhibitor or a receptor-binding compound,
wherein the method comprising reaction of a precursor with a supply of [18F]-fluoride or [18F]NaF, optionally in the presence of [19F]-fluoride, in a suitable solvent,
wherein said precursor of Formula III comprises a metal complex of a chelator of Formula II:
where Z1, Y, Q, p and q are as defined in Formula Za;
where X1a, X2a and X3a are independently Br or Cl; and
where said metal is chosen from: Al3+, Ga3+, In3+, Sc3+, Y3+, Ho3+, Er3+, Tm3+, Yb3+ or Lu3+.

### Claim 23 (depends on 22)

The method of claim 22, where one Q group is present in the imaging agent.

### Claim 24 (depends on 22)

The method of claim 22, where each Y group is covalently conjugated to a different amine donor atom of Z1 in the imaging agent.

### Claim 25 (depends on 22)

The method of any one of claim 22, where in the imaging agent Za is of Formula Zaa or Zab:
where R4 is H, C1-4 alkyl, C2-4 alkoxyalkyl, C1-4 hydroxyalkyl or a Y group;
R5 is H, C1-4 alkyl, C2-4 alkoxyalkyl or C1-4 hydroxyalkyl.

### Claim 26 (depends on 22)

The method of any one of claim 22, where M is Ga3+ or In3+ in the imaging agent.

### Claim 27 (depends on 22)

The method of any one of claim 22, where X1, X2 and X3 are independently Cl, 19F or 18F in the imaging agent.

### Claim 28 (depends on 22)

The method of any one of claim 22, where X1a═X2a═X3a═Cl.

### Claim 29

A chelating agent for use in producing an imaging agent which comprises an 18F-labelled compound of Formula I:
where:
X1, X2 and X3 are independently Br, Cl, 19F or 18F, with the proviso that at least one of X1, X2 and X3 is 18F;
M is Al3+, Ga3+, In3+, Sc3+, Y3+, Ho3+, Er3+, Tm3+, Yb3+ or Lu3+;
Z1 is of Formula Za
where each R3 is independently H, C1-4 alkyl, C2-4 alkoxyalkyl, C1-4 hydroxyalkyl, a Y group or a Q group;
each f is independently 1;
p is 1, 2 or 3;
y is 0 or 1;
Y is independently -(A1)x-Y1 or -(A1)x-Y1-Q where each A1 is independently —CH2— or —O—, provided that Y does not comprise any —O—O— bonds;
wherein x is an integer of value 1 to 6; and
Y1 is —NHRa, —NH(CH2)2NHRa, —NH(CH2)3NHRa, —(C═O)NHRa, —NH(C═O)Ra, —NH(C═NH)NHRa, —ORa or a Y3 group;
Y3 is Arg, Lys, Asn, Gln, Ser, Thr or Tyr;
wherein Ra is independently H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkoxyalkyl or C1-4 hydroxyalkyl;
Q is -L-[BTM];
L is a synthetic linker group of formula -(A)m- wherein each A is independently —CR2—, —CR═CR—, —C═C—, —CR2CO2—, —CO2CR2—, —NRCO—, —CONR—, —CR═N—O—, —NR(C═O)NR—, —NR(C═S)NR—, —SO2NR—, —NRSO2—, —CR2OCR2—, —CR2SCR2—, —CR2NRCR2—, a C4-8 cycloheteroalkylene group, a C4-8 cycloalkylene group, —Ar—, —NR—Ar—, —O—Ar—, —Ar—(CO)—, an amino acid, a sugar or a monodisperse polyethyleneglycol (PEG) building block,
wherein each R is independently chosen from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkoxyalkyl or C1-4 hydroxyalkyl;
m is an integer of value 1 to 20;
each Ar is independently a C5-12 arylene group, or a C3-12 heteroarylene group; BTM is a biological targeting moiety chosen from: a 3-100 mer peptide, an enzyme substrate, an enzyme antagonist, an enzyme agonist, an enzyme inhibitor or a receptor-binding compound,
wherein the chelating agent of Formula IIA:
and
where Z1, Y, Q, p and q are as defined in Formula I.

### Claim 30 (depends on 29)

A metal complex of the chelating agent of Formula IIA as defined in claim 29, where said metal is Al3+, Ga3+, In3+, Sc3+, Y3+, Ho3+, Er3+, Tm3+, Yb3+ or Lu3+.
